Anosmia
Conditions
Interventions
This project is characterized as a randomized, placebo-controlled clinical trial with a sample number (n) = 60 patients with persistent olfactory disorders up to one year after SARS-CoV-2 infection, r
E02.594
Sponsors
Pontifícia Universidade Católica do Paraná
Marco Aurelio Fornazieri
Eligibility
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: Individuals aged between 18 and 55 years; Laboratory-confirmed SARS-CoV-2 infection (reverse transcription polymerase chain reaction, RT-PCR); Complaint of olfactory disorder (anosmia, hyposmia, parosmia or phantosmia) for up to one year after COVID-19
Exclusion criteria
Exclusion criteria: Patients under 18 years of age and as this is a different patient profile; Patients over 55 years of age to avoid the effects of age on the morphology of the olfactory epithelium; Patients with psychiatric or neurological disorders; Patients with previous chronic rhinological pathologies; Patients with recovery from anosmia before recovery from COVID-19; Pregnant patients; Pre-existing manifestations of olfactory alterations; History of traumatic brain injury; Patients who did not complete the follow-up period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the effectiveness of the adjunctive use of photobiomodulation therapy on olfactory disorders in post-COVID-19 patients. | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluate the olfactory function before treatment, after 2 months and 3 months from the start of treatment using the olfactory test (UPSIT). | — |
Countries
Brazil
Contacts
Public ContactMarco Fornazieri
Clinica Olfact
Outcome results
None listed